Egetis Therapeutics ABPDPHF 24 Quick Ratio is 0.68 as of Mar. 2026, which is 87% below its 10-year median of 5.35. GuruFocus rates PDPHF with a GF Score™ of 24/100 and a GF Value™ of $0.64 (Fairly Valued). The stock has 5 warning signs investors should review. Among 1,417 Biotechnology companies, Egetis Therapeutics AB ranks worse than 87.01% on this metric.
Egetis Therapeutics AB has a quick ratio of 0.68. It indicates that the company cannot currently fully pay back its current liabilities.
The historical rank and industry rank for Egetis Therapeutics AB's Quick Ratio or its related term are showing as below:
PDPHF'
s Quick Ratio Range Over the Past 10 Years
Min: 0.68 Med: 5.35 Max: 65.88
Current: 0.68
During the past 13 years, Egetis Therapeutics AB's highest Quick Ratio was 65.88. The lowest was 0.68. And the median was 5.35.
PDPHF's Quick Ratio is ranked worse than 87.01% of 1417
companies
in the Biotechnology industry
Industry Median: 3.6
vs PDPHF: 0.68
Egetis Therapeutics AB (OTCPK:PDPHF) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Egetis Therapeutics AB Quick Ratio Related Terms
Egetis Therapeutics AB Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Egetis Therapeutics AB's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Egetis Therapeutics AB Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Egetis Therapeutics AB's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Egetis Therapeutics AB's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Egetis Therapeutics AB's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Egetis Therapeutics AB (PDPHF) has a Quick Ratio of 0.68 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Egetis Therapeutics AB and its competitors. This is 87% below median its historical median of 5.35. Over the past decade, Egetis Therapeutics AB's Quick Ratio has ranged from 0.68 to 65.88. According to the industry distribution chart, Egetis Therapeutics AB ranks #1233 out of 1417 companies in the Biotechnology industry, placing it in the top 87%.
Is Egetis Therapeutics AB's Quick Ratio too high?
Egetis Therapeutics AB's current Quick Ratio of 0.68 is 87% below median its 10-year median of 5.35. Over the past 10 years, this metric has ranged from a low of 0.68 to a high of 65.88. The Biotechnology industry median Quick Ratio is 3.60. Egetis Therapeutics AB's value of 0.68 is 81.1% below this industry median. Based on the distribution chart, Egetis Therapeutics AB ranks #1233 out of 1417 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Egetis Therapeutics AB has a GF Score™ of 24/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Egetis Therapeutics AB's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Egetis Therapeutics AB ranks #1233 out of 1417 companies for Quick Ratio. This places Egetis Therapeutics AB in the lower half of its industry. The industry median Quick Ratio is 3.60. Egetis Therapeutics AB's value of 0.68 is 81.1% below this benchmark. Historically, Egetis Therapeutics AB's own Quick Ratio has ranged from 0.68 to 65.88 over the past decade. While the company's 10-year median is 5.35 vs. the industry median of 3.60, Egetis Therapeutics AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Egetis Therapeutics AB's current Quick Ratio of 0.68 is 81.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Egetis Therapeutics AB and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Egetis Therapeutics AB's current Quick Ratio is 0.68, which is 87% below median its own 10-year median of 5.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Egetis Therapeutics AB stock overvalued right now?
Based on GuruFocus' analysis, Egetis Therapeutics AB (PDPHF) is currently considered Fairly Valued. The stock's GF Value™ is $0.64, compared to a current price of $0.64 — trading 0.7% below its estimated fair value. The current Quick Ratio is 0.68, which is 87% below median its 10-year median of 5.35 and 81.1% below the Biotechnology industry median of 3.60. Egetis Therapeutics AB's overall GF Score™ is 24/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Egetis Therapeutics AB (PDPHF), the current Quick Ratio is 0.68 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Egetis Therapeutics AB (PDPHF) Overvalued in 2026?
Based on GuruFocus' analysis, Egetis Therapeutics AB stock appears to be undervalued.
The current stock price of $0.64 is trading 0.7% below its estimated GF Value™ of $0.64.
GuruFocus considers Egetis Therapeutics AB to be Fairly Valued.
Key valuation signals for PDPHF:
Quick Ratio: 0.68 (87% below median its 10-year median of 5.35)
GF Value™: $0.64 vs. price of $0.64 (0.7% below fair value)
Industry Position: 81.1% below the Biotechnology median (#1233 of 1417)
No single metric tells the full story. See the PDPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.
24GF Score
Get the complete analysis for PDPHF
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PDPHF has been successfully added to your 
